These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12534449)

  • 21. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.
    Mirdamadi HZ; Sztanek F; Derdak Z; Seres I; Harangi M; Paragh G
    Br J Clin Pharmacol; 2008 Sep; 66(3):366-74. PubMed ID: 18492126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia.
    Puccetti L; Bruni F; Pasqui AL; Pastorelli M; Ciani F; Palazzuoli A; Acampa M; Auteri A
    Eur J Clin Invest; 2008 Jan; 38(1):11-6. PubMed ID: 18173546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
    Jorge PA; Almeida EA; Ozaki MR; Jorge M; Carneiro A
    Arq Bras Cardiol; 2005 Apr; 84(4):314-9. PubMed ID: 15880205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
    Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM
    J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia.
    Inami S; Okamatsu K; Takano M; Takagi G; Sakai S; Sano J; Mizuno K
    Jpn Heart J; 2004 Nov; 45(6):969-75. PubMed ID: 15655272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
    Maclaine GD; Patel H
    Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
    Cromwell WC; Ziajka PE
    Am J Cardiol; 2000 Nov; 86(10):1123-7. PubMed ID: 11074211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
    Hilleman DE; Wurdeman RL; Lenz TL
    Pharmacotherapy; 2001 Apr; 21(4):410-5. PubMed ID: 11310513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
    Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
    Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
    Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
    Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
    Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
    Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.